ABBV · News · 20260829N

Immunology Product Demand and Expansion

AbbVie Inc. · 2026-08-29 · Importance 8 · Surprise 24

Skyrizi continued to drive AbbVie’s Immunology segment in the second quarter of 2026. The report identifies Skyrizi as a key growth product within AbbVie’s immunology portfolio. No additional customer, geographic, channel, or capacity details were provided.

Key facts

• AbbVie continues to expand its immunology and neuroscience portfolio through strategic acquisitions. source
• AbbVie continues to expand its portfolio in high-growth areas like immunology and neuroscience. source
• Skyrizi is continuing to drive AbbVie's immunology segment. source